Publications by authors named "Angela Listi"

Claim this Profile
C
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer.
Francesco Passiglia, Francesco Pepe, Gianluca Russo, Edoardo Garbo, Angela Listì

Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).
Francesco Passiglia, Angela Listì, Paolo Bironzo, Alessandra Merlini, Federica Benso

J Thorac Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify Mutation Profiler.
Francesco Pepe, Gianluca Russo, Nadia Barraco, Marco Bono, Angela Listì

Oncol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.
Francesco Passiglia, Luisella Righi, Paolo Bironzo, Angela Listì, Giovanni Farinea

Clin Cancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience.
Francesco Pepe, Gianluca Russo, Alessandro Venuta, Claudia Scimone, Mariantonia Nacchio

Oncol Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
Giovanni Farinea, Veronica Crespi, Angela Listì, Luisella Righi, Paolo Bironzo

J Thorac Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.
Paolo Bironzo, Massimiliano Cani, Francesca Jacobs, Valerio M Napoli, Angela Listì

Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity.
Francesca Bersani, Francesca Picca, Deborah Morena, Luisella Righi, Francesca Napoli

J Exp Clin Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer.
Annapaola Mariniello, Fabrizio Tabbò, Davide Indellicati, Martina Tesauro, Nicole Alessia Rezmives

Cells· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center.
Caterina De Luca, Francesco Pepe, Pasquale Pisapia, Antonino Iaccarino, Luisella Righi

Per Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostics of -Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience.
Marika Sculco, Marta La Vecchia, Anna Aspesi, Michela Giulia Clavenna, Michela Salvo

Diagnostics (Basel)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the clinical management of -mutant advanced non-small cell lung cancer: a literature review.
Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Angela Listì, Edoardo Garbo

Transl Lung Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repositioning PARP inhibitors in the treatment of thoracic malignancies.
Francesco Passiglia, Maria Lucia Reale, Valeria Cetoretta, Elena Parlagreco, Francesca Jacobs

Cancer Treat Rev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NUPR1 interacts with eIF2α and is required for resolution of the ER stress response in pancreatic tissue.
Maria Teresa Borrello, Patricia Santofimia-Castaño, Marco Bocchio, Angela Listi, Nicolas Fraunhoffer

FEBS J· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas.
Luisella Righi, Alberto Righi, Simona Vatrano, Ida Rapa, Angela Listì

Virchows Arch· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.].
Immacolata Esposito, Silvia Calabria, Carlo Piccinni, Alice Addesi, Letizia Dondi, Angela Listi

Recenti Prog Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.
Paolo Bironzo, Maria Lucia Reale, Tessa Sperone, Fabrizio Tabbò, Andrea Caglio

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.
Francesca Napoli, Angela Listì, Vanessa Zambelli, Gianluca Witel, Paolo Bironzo

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.
Umberto Malapelle, Sara Pilotto, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia

Crit Rev Oncol Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response.
Maria Teresa Borrello, Maria Rita Emma, Angela Listi, Marion Rubis, Sergiu Coslet

FASEB J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Umberto Malapelle, Francesco Passiglia, Chiara Cremolini, Maria Lucia Reale, Francesco Pepe

Eur J Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Francesco Passiglia, Paolo Bironzo, Luisella Righi, Angela Listì, Francesca Arizio

Clin Lung Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer.
Caterina De Luca, Francesco Pepe, Antonino Iaccarino, Pasquale Pisapia, Luisella Righi

Cancers (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Nadia Barraco, Marco Bono

Adv Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.
Francesco Passiglia, Antonio Galvano, Marta Castiglia, Lorena Incorvaia, Valentina Calò

Ther Adv Med Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis